Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.44 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11951618 | 0.92 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2GAAMAPTHPGD | |
| SCHEMBL26879496 | 0.90 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2GAAMAPTHPGD | |
| SCHEMBL84033 | 0.87 | PPARG (0.53) | ALDH1A1MAPTHPGDL3MBTL1CYP1A2 | |
| SCHEMBL11951653 | 0.85 | HDAC4 (0.43) | ALDH1A1SMN1; SMN2GAAMAPTHPGD | |
| SCHEMBL6376390 | 0.85 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2GAAMAPTHPGD | |
| SCHEMBL16956655 | 0.85 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2GAAMAPTHPGD | |
| SCHEMBL12180453 | 0.85 | PDE4B (0.44) | ALDH1A1SMN1; SMN2GAAMAPTHPGD | |
| SCHEMBL24780244 | 0.83 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2GAAMAPTHPGD | |
| SCHEMBL21276073 | 0.83 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2GAAMAPTHPGD | |
| SCHEMBL11951557 | 0.83 | HDAC8 (0.49) | ALDH1A1SMN1; SMN2GAAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402908-A1 | CXCR6 INHIBITORS AND METHODS OF USE | Sanford Burnham Prebys Medical Discovery Institute | 2022-12-22 | — | — | US | disclosed |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMA (US) | 2017-05-25 | — | — | US | disclosed |
| US-9511067-B2 | Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-06 | — | — | US | disclosed |
| US-9403839-B2 | Pyran-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-02 | — | — | US | disclosed |
| US-9181273-B2 | Morpholine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150174127-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-25 | — | — | US | disclosed |
| US-20150025073-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-01-22 | — | — | US | disclosed |
| US-20150005304-A1 | Pyran-Spirocyclic Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-01 | — | — | US | disclosed |
| US-8916565-B2 | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-23 | — | — | US | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-08-02 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7807690-B2 | 2,3-dihydro-iminoisoindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20100184981-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | CLARK RICHARD | 2010-07-22 | — | — | US | disclosed |
| US-20090270433-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7605171-B2 | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists | MERCK & CO., INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080249093-A1 | (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists | MERCK & CO., INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174127-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | ALDH1A1 1663/4885SMN1; SMN2 1522/4885GAA 2899/4885 |
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | ALDH1A1 1663/4885SMN1; SMN2 1522/4885GAA 2899/4885 |
| US-20100184981-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | SERPINC1, F7, F2 | ALDH1A1 1133/4885SMN1; SMN2 3093/4885GAA 2251/4885 |
| US-20220402908-A1 | CXCR6 INHIBITORS AND METHODS OF USE | CXCR6, CXCR1, CXCR5 | ALDH1A1 2641/4885SMN1; SMN2 4732/4885GAA 4721/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | ALDH1A1 1614/4885SMN1; SMN2 1198/4885GAA 2915/4885 |
| US-20150025073-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPM5, KCNQ1 | ALDH1A1 1738/4885SMN1; SMN2 831/4885GAA 2974/4885 |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ1, KCNC1 | ALDH1A1 1764/4885SMN1; SMN2 1515/4885GAA 2794/4885 |
| US-20150005304-A1 | Pyran-Spirocyclic Piperidine Amides as Modulators of Ion Channels | TRPV1, KCNJ2, KCNJ1 | ALDH1A1 1467/4885SMN1; SMN2 1976/4885GAA 3375/4885 |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ5, KCNJ1 | ALDH1A1 1663/4885SMN1; SMN2 1522/4885GAA 2899/4885 |
| US-20090270433-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | SERPINC1, F7, F2 | ALDH1A1 1107/4885SMN1; SMN2 3269/4885GAA 2310/4885 |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ1, KCNC1 | ALDH1A1 1764/4885SMN1; SMN2 1515/4885GAA 2794/4885 |
| US-20080249093-A1 | (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists | S1PR1, S1PR3, S1PR5 | ALDH1A1 740/4885SMN1; SMN2 2376/4885GAA 3443/4885 |
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | ALDH1A1 710/4885SMN1; SMN2 3935/4885GAA 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.